Endothelin-1 plasma concentration in children and adolescents with atherogenic risk factors;Stȩżenie endoteliny-1 u dzieci i młodzieży z czynnikami ryzyka miażdżycy

Kardiologia Polska

Volumn 61, Issue 10, 2004, Pages 329-338

  Głowińska, Barbara ^a   Urban, Mirosława ^a   Hryniewicz, Andrzej ^a   Peczyńska, Jadwiga ^a   Florys, Bozena ^a   Al Hwish, Mortada ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Adolescents; Atherogenic risk factors; Children; Endothelial dysfunction; Endothelin 1

Indexed keywords

CHOLESTEROL; ENDOTHELIN 1; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OBESITY; PATHOGENESIS; RISK FACTOR; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 8444238229     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bednarska-Chabowska D., Adamiec R., Rychlik-Golema W. et al.: Wybrane aspekty czynności śródbłonka. 1. Rola śródblłonka w utrzymaniu równowagi hematologicznej i kra̧żeniowej. Pol. Merk. Lek. 2001,70, 322-327.
2. Iglarz M., Schiffrin E.L.: Role of endothelin-1 in hypertension. Curr. Hypertens. Rep. 2003, 5, 144-8.
3. Hladovec J., Prerovsky I.: Endothelial lesion in hypertension. Cor. Vasa 1989, 31, 51-4.
4. Kosmala W.: Dysfunkcja śródbłonka w nadciśnieniu tȩtniczym - implikacje kliniczne. Pol. Merk. Lek. 2001, 70, 333-335.
5. Stewart D.J.: Impact of endothelin-1 on vascular structure and function. Am. J. Cardiol. 1998, 82, 14S-16S.
6. Puddu P., Puddu G.M., Zaca F. et al.: Endothelial dysfunction in hypertension. Acta Cardiol. 2000, 55, 221-32.
7. Broda G., Zdrojewski T.: Czy w Polsce na progu XXI wieku nadciśnienie tȩtnicze jest prawidłowo diagnozowane i skutecznie leczone? Kardiol. Pol. 2002, 56, 230-238.
8. Lieberman E.: Pediatric hypertension, clinical perspective. Mayo Clin. Proc. 1994, 69, 1098-107.
9. Nohria A., Garrett L., Johnson W. et al.: Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension 2003, 42, 43-8.
10. Saito Y., Nakao K., Mukoyama M. et al.: Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 1990, 322, 205.
11. Schiffrin E.L.: Role of endothelin-1 in hypertension and vascular disease. Am. J. Hypertens. 2001, 14, 83S-89S.
12. Node K., Kitakaze M., Yoshikawa H. et al.: Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997, 30, 405-8.
13. Schneider M.P., Hilgers K.F., Klingbeil A.U. et al.: Plasma endothelin is increased in early essential hypertension. Am. J. Hypertens. 2000, 13, 579-85.
14. Taddei S., Virdis A., Ghiadoni L. et al.: Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999, 100, 1680-3.
15. Pokharel D., Sharma U.C., Pinto Y.M.: Left ventricular hypertrophy: vitreous intentions, malign consequences. Int. J. Bioch. Cell. Biol. 2003, 35, 802-806.
16. Parissis J.T., Venetsanou K.F., Mentzikof D.G. et al.: Plasma levels of soluble cellular adhesion molecules in patients with arterial hypertension. Correlations with plasma endothelin-1. Eur. J. Intern. Med. 2001, 12, 350-356.
17. Winkler G., Lakatos P., Salamon F. et al.: Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabet. Med. 1999, 16, 207-11.
18. Asai T., Ohkubo T., Katsuya T. et al.: Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects: the Ohasama Study. Hypertension 2001, 38, 1321-4.
19. Irving R.J., Noon J.P., Watt G.C. et al.: Activation of the endothelin system in insulin resistance. Qjm. 2001, 94, 321-6.
20. Barton M., Traupe T., Haudenschild C.C.: Endothelin, hypercholesterolemia and atherosclerosis. Coron. Artery Dis. 2003, 14, 477-90.
21. Xiong Y., Tanaka H., Richardson J.A. et al.: Endothelin-1 stimulates leptin production in adipocytes. J. Biol. Chem. 2001, 276, 28471-7.
22. Jin J.J., Nakura J., Wu Z. et al.: Association of endothelin-1 gene variant with hypertension. Hypertension 2003, 41, 163-7.
23. Hopfner R.L., Gopalakrishnan V.: Endothelin: emerging role in diabetic vascular complications. Diabetologia 1999, 42, 1383-94.
24. Migdalis I.N., Kalogeropoulou K., Iliopoulou V. et al.: Plasma levels of endothelin, lipid peroxides and prostacyclin in diabetic patients with macroangiopathy. Diabetes. Res. Clin. Pract. 2001, 54, 129-36.
25. Cardillo C., Kilcoyne C.M., Cannon R.O. 3rd et al.: Increased activity of endogenous endothelin in patients with hypercholesterolemia. J. Am. Coll. Cardiol. 2000, 36, 1483-8.
26. Haak T., Marz W., Jungmann E. et al.: Elevated endothelin levels in patients with hyperlipoproteinemia. Clin. Investig. 1994, 72, 580-4.
27. Lundman P., Eriksson M.J., Silveira A. et al.: Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand factor, and endothelin-1). Am. J. Cardiol. 2003, 91, 1128-31.
28. Mangieri E., Tanzilli G., Barilla F. et al.: Handgrip increases endothelin-1 secretion in normotensive young male offspring of hypertensive parents. J. Am. Coll. Cardiol. 1998, 31, 1362-6.
29. Nicolaidou P., Georgouli H., Matsinos Y. et al.: Endothelin-1 in children with acute poststreptococcal glomerulonephritis and hypertension. Pediatr. Int. 2003, 45, 35-8.
30. Wojakowski W., Gminski J.: Plasma levels of von willebrand factor, endothelin-1, prostacyclin and thromboxane in children from families with high risk of premature coronary artery disease. Scand. J. Clin. Lab. Invest. 2001, 61, 317-23.
31. Dashwood M.R., Txui J.C.: Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002, 160, 297-304.
32. Bohm F., Ahlborg G., Johansson B.L. et al.: Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 674-9.
33. Hlubocka Z., Umnerova V., Heller S. et al.: Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J. Hum. Hypertens. 2002, 16, 557-62.
34. Maeda S., Miyauchi T., Kakiyama T. et al.: Effects of exercise training of 8 weeks and detraining on plasma levels of endothelium-derived factors, endothelin-1 and nitric oxide, in healthy young humans. Life Sci. 2001, 69, 1005-16.